Regeneron
$450.019876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$450.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$5.41 (-1.18%) Today
-$3.18 (-0.70%) As of 12:51 PM UTC after-hours
Why Robinhood?
You can buy or sell Regeneron and other stocks, options, and ETFs commission-free!
About REGN
Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. The listed name for REGN is Regeneron Pharmaceuticals, Inc. Common Stock.
CEO
Leonard S. Schleifer
Employees
9,123
Headquarters
Tarrytown, New York
Founded
1988
Market Cap
49.55B
Price-Earnings Ratio
15.02
Dividend Yield
—
Average Volume
1.32M
High Today
$465.00
Low Today
$448.33
Open Price
$460.48
Volume
1.13M
52 Week High
$664.64
52 Week Low
$418.01
REGN News
Reuters1h
EU regulator endorses Regeneron antibody cocktail to treat COVID-19
Feb 26 (Reuters) - Europe's medicines regulator said on Friday that an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COV
Analyst Ratings
67%
of 27 ratings
Buy
67%
Hold
33%
Sell
0%
REGN Earnings
$0.00
$3.18
$6.35
$9.53
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 4, Pre-Market